British Evonetix Ltd has added US$$24m to its existing US$30m Series B financing round. The new financing was led by existing investor Foresite Capital.
mRNA vaccine pioneer CureVac N.V. has announced that it will sell US$200m of its common shares in an underwritten public offering.
South Korean Chong Kun Dang Pharm has licenced access to Amsterdam-based Synaffix BV’s propietary ADC platform.
A new platform is set to facilitate the exchange of information on the optimisation of the electronic reporting system CTIS.
British researchers have linked higher consumption of ultra-processed foods to an increased risk of developing and dying from cancer.
Asher Biotherapeutics Inc has expanded its manufacturing agreement with Lonza to include the manufacturing of AB248.
Evotec SE and Janssen Biotech Inc have agreed to co-develop targeted immuno-oncological therapies.
pixabay.com/SD-PicturesA new study adds weight to ongoing legal and political investigations against ExxonMobil for deliberate climate malfeasance.
With Sunstone Life Siences A/S as a new investor, Belgian remyelination specialist Rewind Therapeutics has increased its 2018 Series A funding.
British researchers have created a new polymer material that may help to prevent urinary tract infections caused by catheters